Premium
Pegfilgrastim compared with filgrastim after high‐dose melphalan and autologous hematopoietic peripheral blood stem cell transplantation in multiple myeloma patients
Author(s) -
Martino Massimo,
Praticò Giulia,
Messina Giuseppe,
Irrera Giuseppe,
Massara Elisabetta,
Messina Giuseppe,
Console Giuseppe,
Iacopino Pasquale
Publication year - 2006
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/j.1600-0609.2006.00736.x
Subject(s) - pegfilgrastim , filgrastim , medicine , neutropenia , melphalan , multiple myeloma , hematopoietic stem cell transplantation , febrile neutropenia , transplantation , gastroenterology , surgery , chemotherapy , oncology
We undertook a comparative study of Pegfilgrastim vs. Filgrastim after high‐dose melphalan and autologous peripheral blood stem cell transplantation (APBSCT) in multiple myeloma (MM) patients. Thirty‐seven consecutive patients were randomly assigned to receive a single 6 mg dose of Pegfilgrastim on day 1 post‐transplant ( n = 18 patients) vs. daily subcutaneous injections of Filgrastim 5 μ g/kg ( n = 19 patients) starting on day 5 post‐transplant. The median duration of grade 4 neutropenia in the Pegfilgrastim and Filgrastim groups was 5 and 6 d, respectively ( P = ns). The results for the two groups were also not significantly different for time to neutrophil and platelet recovery, but incidence of febrile neutropenia (61.1% vs. 100%, P = 0.003) and duration of febrile neutropenia (1.5 d vs. 4 d, P = 0.005), were lower in the Pegfilgrastim arm. After initial haematopoietic reconstitution, we observed significantly higher value of leukocytes × 10 9 L on day 15 (6.0 vs. 2.7, P = 0.004), in the Pegfilgrastim group compared with the Filgrastim group. This study shows that a single injection Pegfilgrastim can be used with safety and efficacy similar to those provided by daily injections of Filgrastim and it is associated with a decrease incidence of infectious events after APBSCT in MM patients.